FDA, Bodee LLC issue nationwide recall of Encore Tablets
FDA Approves Dupilumab for Treatment of Chronic Spontaneous Urticaria
The approval is based on 2 phase 3 studies demonstrating reductions in itch severity and urticaria activity as a composite of itch and hives at 24 weeks.
Looking to the Future of Independent Pharmacy
Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.
FDA Grants Yuflyma Interchangeability Designation for Humira
The FDA approved adalimumab-aaty in May 2023 for 8 indications, including rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.
Podcast: Pharmacy Financing With First Financial Bank
Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.
FDA Grants Fast Track Designation for Potential Bird Flu Vaccine
The designation addresses the unmet need for prevention of H5N1, which remains a global health risk, and a phase 1 trial of the vaccine was initiated in November 2024.
FDA Approves Generic Liraglutide for Type 2 Diabetes
As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.
